Alina Tănase
YOU?
Author Swipe
View article: Real-world patient outcomes with Blinatumomab and Inotuzumab in adult relapsed/refractory B-cell acute lymphoblastic leukemia: a retrospective analysis from two Romanian oncology centers
Real-world patient outcomes with Blinatumomab and Inotuzumab in adult relapsed/refractory B-cell acute lymphoblastic leukemia: a retrospective analysis from two Romanian oncology centers Open
Introduction The management of adult relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) remains a significant challenge, with patients presenting particularly poor historical outcomes. Novel immunotherapies, such as Blinat…
View article: Advances in measurable residual disease assessment for acute myeloid leukemia: from cytogenetics and molecular biology to assessment of the methylation pattern and surface-enhanced Raman scattering as emerging technologies
Advances in measurable residual disease assessment for acute myeloid leukemia: from cytogenetics and molecular biology to assessment of the methylation pattern and surface-enhanced Raman scattering as emerging technologies Open
Measurable residual disease (MRD) assessment has become a cornerstone in the management of acute myeloid leukemia (AML), offering critical prognostic information and guiding post-remission therapy. Conventional MRD detection methods, inclu…
View article: CARing about autoimmune disorders. Use of chimeric antigen receptor engineered T-cells in autoimmune diseases
CARing about autoimmune disorders. Use of chimeric antigen receptor engineered T-cells in autoimmune diseases Open
Chimeric Antigen Receptor (CAR) T cell therapy, initially developed for hematologic malignancies, has recently emerged as a promising modality for treating autoimmune diseases. This review explores the evolving role of CAR T cells in repro…
View article: Allogeneic hematopoietic cell transplant in cutaneous T-cell lymphomas: recommendations from the EBMT PH&G Committee
Allogeneic hematopoietic cell transplant in cutaneous T-cell lymphomas: recommendations from the EBMT PH&G Committee Open
This manuscript provides expert recommendations on the role of allogeneic hematopoietic cell transplantation (allo-HCT) for cutaneous T-cell lymphoma (CTCL), specifically Mycosis Fungoides (MF) and Sezary Syndrome (SS). Critical aspects su…
View article: Allogeneic haematopoietic cell transplant in cutaneous T‐cell lymphomas: Recommendations from the <scp>EBMT PH</scp>&G Committee
Allogeneic haematopoietic cell transplant in cutaneous T‐cell lymphomas: Recommendations from the <span>EBMT PH</span>&G Committee Open
This manuscript provides expert recommendations on the role of allogeneic haematopoietic cell transplantation (allo‐HCT) for cutaneous T‐cell lymphoma (CTCL), specifically mycosis fungoides (MF) and Sezary syndrome (SS). Critical aspects s…
View article: Conditioning regimens in pediatric myeloid malignancies undergoing allogeneic HSCT: a comparative single-center study
Conditioning regimens in pediatric myeloid malignancies undergoing allogeneic HSCT: a comparative single-center study Open
Introduction Optimal conditioning regimen for pediatric myeloid malignancies is still subject for debate. This single-center retrospective study compares the efficacy and toxicity profiles of three conditioning strategies, myeloablative co…
View article: Challenges in the preclinical design and assessment of CAR-T cells
Challenges in the preclinical design and assessment of CAR-T cells Open
The advent of immunotherapy in the treatment of cancer has opened a new dimension in the management of this complex multifaceted disease, bringing hope to many patients whose tumors have failed to respond to conventional therapies. The ado…
View article: Incidence and risk factors for chronic kidney disease after hematopoietic stem cell transplantation
Incidence and risk factors for chronic kidney disease after hematopoietic stem cell transplantation Open
As the prognostic of hematopoietic stem cell transplantation survivors is improving, CKD emerges as an important comorbidity, with hematologic disease length and baseline eGFR being independent risk factors for renal dysfunction.
View article: Allogeneic haematopoietic cell transplantation in peripheral T-cell lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee
Allogeneic haematopoietic cell transplantation in peripheral T-cell lymphoma: recommendations from the EBMT Practice Harmonisation and Guidelines Committee Open
Allogeneic haematopoietic cell transplantation (HCT) is a potentially curative therapy for peripheral T-cell lymphoma; however, to date, there are no standardised and detailed guidelines for its application. To address gaps in clinical pra…
View article: Adipose Tissue-Derived Mediators in Multiple Myeloma: Linking Obesity to Bone Disease via Inflammatory Pathways
Adipose Tissue-Derived Mediators in Multiple Myeloma: Linking Obesity to Bone Disease via Inflammatory Pathways Open
In patients diagnosed with multiple myeloma (MM), the primary complaints at the time of diagnosis are often related to bone involvement, significantly impacting quality of life and increasing both morbidity and mortality. Obesity is associ…
View article: Adoptive cellular therapies in multiple myeloma
Adoptive cellular therapies in multiple myeloma Open
Plasma cell myeloma (multiple myeloma) is a blood cancer characterized by the clonal proliferation of plasma cells in the bone marrow. Treatment strategies evolve year by year, new drugs getting Food and Drug Administration (FDA)-approved …
View article: Adoptive cellular therapies in non-Hodgkin lymphomas
Adoptive cellular therapies in non-Hodgkin lymphomas Open
Lymphomas are a group of malignant proliferations of B, T or NK-lymphoid cells at different stages of maturation. While they primarily occur in lymph nodes or lymphatic tissues, they can also involve bone marrow, blood, or other organs. De…
View article: Insights into Pediatric GATA2-Related MDS: Unveiling Challenges in Clinical Practice
Insights into Pediatric GATA2-Related MDS: Unveiling Challenges in Clinical Practice Open
Background: GATA2-related myelodysplastic syndrome (GATA2-MDS) is a unique predisposition syndrome with a high risk of leukemic transformation. This systematic review synthesizes current literature and presents two illustrative pediatric G…
View article: Tuberculosis after hematopoietic cell transplantation: retrospective study on behalf of the Infectious Diseases Working Party of the EBMT
Tuberculosis after hematopoietic cell transplantation: retrospective study on behalf of the Infectious Diseases Working Party of the EBMT Open
Tuberculosis (TB) is rare following hematopoietic cell transplantation (HCT). In this multinational retrospective study, we report the frequency, characteristics, and outcome of TB following HCT performed during 2000-2019. Fifty-two patien…
View article: The Evolving Landscape in Multiple Myeloma: From Risk Stratification to T Cell-Directed Advanced Therapies
The Evolving Landscape in Multiple Myeloma: From Risk Stratification to T Cell-Directed Advanced Therapies Open
Multiple myeloma is biologically and clinically a complex and heterogeneous disease which develops late in life, with the median age at the time of initial diagnosis being 66 years. In 1975, Durie and Salmon developed the first broadly ado…
View article: A Review of Immunological Evaluation of Patients with Recurrent Spontaneous Abortion (RSA)
A Review of Immunological Evaluation of Patients with Recurrent Spontaneous Abortion (RSA) Open
In approximately half of the recurrent spontaneous abortion (RSA) cases, the underlying cause is unknown. However, most unexplained miscarriages are thought to be linked to immune dysfunction. This review summarizes the current evidence re…
View article: Outcome of Patients with HTLV-1 Adult T-Cell Leukemia/Lymphoma (ATL) after Allogeneic SCT: Results of the EBMT LWP
Outcome of Patients with HTLV-1 Adult T-Cell Leukemia/Lymphoma (ATL) after Allogeneic SCT: Results of the EBMT LWP Open
Introduction: HTLV-1 positive ATL is an uncommon aggressive malignancy with a dismal prognosis. Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a potentially curative treatment modality for these patients, but most of them…
View article: Renal Complications Following Hematopoietic Stem Cell Transplantation
Renal Complications Following Hematopoietic Stem Cell Transplantation Open
Renal complications following hematopoietic stem cell transplantation (HSCT) pose substantial clinical challenges and impact patient outcomes. This chapter provides an in-depth analysis of the renal complications that may arise post-HSCT, …
View article: CNS manifestations in acute and chronic graft-versus-host disease
CNS manifestations in acute and chronic graft-versus-host disease Open
Despite the growing evidence supporting the existence of CNS involvement in acute and chronic graft-versus-host disease (CNS-GvHD), the characteristics and course of the disease are still largely unknown. In this multicentre retrospective …
View article: Is Contrast-Enhanced Ultrasonography a New, Reliable Tool for Early-Graft-versus-Host Disease Diagnosis?
Is Contrast-Enhanced Ultrasonography a New, Reliable Tool for Early-Graft-versus-Host Disease Diagnosis? Open
Acute gastrointestinal graft-versus-host disease (GI aGVHD) is a significant and life-threatening complication in patients undergoing allogeneic stem cell transplantation (allo-SCT). Early diagnosis of GI aGVHD is crucial for improving pat…
View article: “Lazarus Response” When Feto-Maternal Microchimerism Kicks in: Spontaneous Remission in Refractory Primary Mediastinal B Cell Lymphoma Following Twin Pregnancy
“Lazarus Response” When Feto-Maternal Microchimerism Kicks in: Spontaneous Remission in Refractory Primary Mediastinal B Cell Lymphoma Following Twin Pregnancy Open
Background: Spontaneous remission of cancer is a rare and poorly understood phenomenon characterized by complete or partial remission of a malignancy in the absence of or with inadequate treatment. The underlying mechanism for such occurre…
View article: Southern African Origin of HTLV-1 in Romania
Southern African Origin of HTLV-1 in Romania Open
In Europe, most HTLV-1-infected individuals originate from highly endemic regions such as West Indies, sub-Saharan Africa, and South America. The only genuine endemic region for HTLV-1 in Europe is Romania where ATL series have been report…
View article: Unrelated donor transplantation with posttransplant cyclophosphamide vs ATG for myelodysplastic neoplasms
Unrelated donor transplantation with posttransplant cyclophosphamide vs ATG for myelodysplastic neoplasms Open
It has been reported in prospective randomized trials that antithymocyte globulin (ATG)–based graft-versus-host disease (GVHD) prophylaxis has benefits in the setting of allogeneic hematopoietic stem cell transplantation (allo-HSCT) with u…
View article: Donor KIR genotype based outcome prediction after allogeneic stem cell transplantation: no land in sight
Donor KIR genotype based outcome prediction after allogeneic stem cell transplantation: no land in sight Open
Optimizing natural killer (NK) cell alloreactivity could further improve outcome after allogeneic hematopoietic cell transplantation (alloHCT). The donor’s Killer-cell Immunoglobulin-like Receptor (KIR) genotype may provide important infor…
View article: Unlocking protein-based biomarker potential for graft-versus-host disease following allogenic hematopoietic stem cell transplants
Unlocking protein-based biomarker potential for graft-versus-host disease following allogenic hematopoietic stem cell transplants Open
Despite the numerous advantages of allogeneic hematopoietic stem cell transplants (allo-HSCT), there exists a notable association with risks, particularly during the preconditioning period and predominantly post-intervention, exemplified b…
View article: Outcomes of allogeneic stem cell transplantation in acute leukemias – single centre study
Outcomes of allogeneic stem cell transplantation in acute leukemias – single centre study Open
Aim: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is recommended in first complete remission (CR) for adverse and intermediate-risk acute myeloid leukemia (AML) and not recommended for AML patients with favourable disease…